Immunogenic composition
By developing a trivalent vaccine containing antigens of Salmonella Typhimurium, Salmonella Enteritidis, and Salmonella Typhimurium, as well as a quadrivalent vaccine conjugated with Salmonella Paratyphi A antigen, the shortcomings of existing vaccines in preventing Salmonella Typhimurium and Salmonella Paratyphi A infection have been addressed, achieving highly efficient immunogenicity and preventive effect while avoiding antigen interference.
Patent Information
- Application Number
- CN202480048259.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-29
- Filing Date
- 2024-07-19
- Publication Date
- 2026-02-17
AI Technical Summary
Existing vaccines are insufficient to effectively prevent and control infections of Salmonella Typhi and Salmonella Paratyphi A, especially in areas where multidrug-resistant strains are prevalent, and existing vaccines may also have antigenic interference issues.
A trivalent vaccine containing antigens of Salmonella Typhimurium, Salmonella Enteritidis, and Salmonella Typhimurium, as well as a quadrivalent vaccine conjugated with Salmonella Paratyphi A antigen, were developed. GMMA was used to enhance the immune response, antigen interference was avoided, and the O-antigen was activated to conjugate with the carrier protein through the CDAP chemical method to enhance immunogenicity.
It achieved high immunogenicity against Salmonella Typhi and Salmonella Paratyphi A, enhanced the immune response against these antigens, and provided an effective preventive measure without antigen interference.